After opening the day in red share markets in India witnessed choppy trading activity and are presently trading well below the dotted line. Sectoral indices are trading on a mixed note, with stocks in the realty sector and stocks in the metal sector witnessing maximum buying interest. While stocks in the banking sector are leading the losses.

The BSE Sensex is trading down by 435 points (down 1.3%) and the NSE Nifty is trading down by 131 points (down 1.2%). Meanwhile, the BSE Mid Cap index is trading down by 0.2%, while the BSE Small Cap index is trading down by 0.1%. The rupee is trading at 64.29 to the US$.

In news from stocks in the pharma sectorJubilant Lifesciences share price is among the most active stocks today after the company said its subsidiary has received final approval from the US Food and Drug Administration (USFDA) Amantadine Hydrochloride tablets, an anti-viral and anti-Parkinsons drug.

The approved drug, generic version of Symmetrel of Endo, is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. It is also indicated in the treatment of Parkinsonism and drug-induced extrapyramidal reactions.

As on December 31, 2017, Jubilant Life Sciences had 86 ANDAs for oral solids filed in the US, of which 56 have been approved and 12 injectable filings, of which 10 had been approved, the filing added.

Jubilant Lifesciences share price was trading down by 2.5%.

The Indian pharmaceutical industry has come under a lot of regulatory pressure in the past few years.

The sector has faced great volatility over the years.

We had written about the current predicament of Indian pharma companies in one of the premium editions of the 5 Minute WrapUp:

  • Over the past few years, risk in the US markets has increased. The US Food and Drug Administration has become stricter on products entering US borders. Surprise inspections have increased and companies are being issued warning letters. This has impacted the business and earnings of Indian pharma players, causing major volatility for the sector.
  • Print Friendly, PDF & Email